A Sticky Situation: Variable Agreement Between Platelet Function Tests Used to Assess Anti-platelet Therapy Response.

Area of Science:

• Cardiology
• Clinical Chemistry
• Pharmacology

Background:

• Platelet function testing is crucial for managing antiplatelet therapy and preventing thromboembolic events.
• Significant variability exists between different testing methods, posing challenges for consistent patient management.

Purpose of the Study:

• To evaluate the agreement of four distinct testing platforms in monitoring the antiplatelet effects of aspirin (ASA) and P2Y12 inhibitors (P2Y12-I).

Main Methods:

• Analyzed blood and urine specimens from 20 patients on dual antiplatelet therapy.
• Utilized light transmission aggregometry (LTA), whole blood aggregometry (WBA), VerifyNow PRUTest, and AspirinWorks.
• Calculated agreement indices using pre-defined cutoff values and Pearson's correlation coefficient.

Main Results:

• Overall agreement between platforms ranged from 35% to 75%.
• LTA and VerifyNow showed the highest agreement for P2Y12-I response (75%).
• Agreement for ASA response was lower, with LTA and AspirinWorks showing moderate agreement (60%) and WBA showing the weakest agreement.

Conclusions:

• LTA is supported for monitoring dual antiplatelet therapy, with VerifyNow as a viable alternative for P2Y12-I response.
• The study highlights the need for careful interpretation of results across different platelet function assays.
• Future research should integrate findings from these varied platforms with patient outcomes.